NRGN and Alzheimer disease: In INTERCEPT-AD, three administrations of sabirnetug resulted in lowering CSF levels of biomarkers that are elevated in AD, pTau181 and tTau, as well as the synaptic injury markers VAMP2 and neurogranin.